Walleye Capital LLC Affimed N.V. Transaction History

Walleye Capital LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $1.24 Million - $2.1 Million	632,946 Added 160.6%	1,027,053 $2.12 Million
Q2 2022 Aug 08, 2022	BUY	$2.27 - $4.86 $894,622 - $1.92 Million	394,107 New	394,107 $1.09 Million
Q1 2021 May 17, 2021	SELL	$5.12 - $8.48 $68,904 - $114,123	-13,458 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$3.16 - $7.03 $42,527 - $94,609	13,458 New	13,458 $78,000
Q1 2019 May 15, 2019	SELL	$3.05 - $4.34 $140,123 - $199,388	-45,942 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$1.45 - $6.15 $66,615 - $282,543	45,942 New	45,942 $200,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.